NGR-hTNF Administered in Combination With a Standard Oxaliplatin Based Regimen in Patients With Metastatic Colorectal Cancer

Colon Cancer Clinical Trial

Official title:

NGR005: Pilot Study of NGR-hTNF Administered at Low and High Doses in Combination With a Standard Oxaliplatin Based Regimen in Patients With Metastatic Colorectal Cancer

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00675012
• Other study ID #: NGR005
• Secondary ID: 2007-003668-24
• Status: Completed
• Phase: Phase 2
• First received: May 5, 2008
• Last updated: May 29, 2014
• Start date: December 2007
• Est. completion date: May 2013

Study information

• Verified date: May 2014
• Source: MolMed S.p.A.
• Contact: n/a
• Is FDA regulated: No
• Health authority: Italy: Ethics Committee
• Study type: Interventional

Clinical Trial Summary

The main objective of the trial is to document the safety of NGR-hTNF administered at low and high doses in combination with a standard oxaliplatin based regimen in patients with metastatic colorectal cancer not amenable to any clinical improvement by current standard treatments

Description:

Phase II, open-label, non-randomized study that will be conducted in two sequential cohorts of patients. Patients with metastatic colorectal cancer not amenable to any clinical improvement by current standard treatments are planned to be enrolled.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 24
• Est. completion date: May 2013
• Est. primary completion date: December 2010
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients = 18 years with metastatic colorectal cancer (CRC) treated with no more than three standard systemic regimens (including biologic agents) for metastatic disease

• Life expectancy more than 3 months

• ECOG Performance status 0-1

• Adequate baseline bone marrow, hepatic and renal function, defined as follows:

• Neutrophils >1.5 x 10^9/L and platelets > 100 x 10^9/L

• Bilirubin <1.5 x ULN

• AST and/or ALT <2.5 x ULN in absence of liver metastasis

• AST and/or ALT <5 x ULN in presence of liver metastasis

• Serum creatinine <1.5 x ULN

• Creatinine clearance (estimated according to Cockcroft-Gault formula) = 50 ml/min

• Patients may have had prior therapy providing the following conditions are met:

• Chemotherapy, radiation therapy, hormonal therapy or immunotherapy: wash-out period of 28 days before start treatment

• Surgery: wash-out period of 14 days before start treatment

• Patients must give written informed consent to participate in the study

Exclusion Criteria:

• Concurrent anticancer therapy

• Patients must not receive any other investigational agents while on study

• Patients with myocardial infarction within the last six (6) months, unstable angina, New York Heart Association (NYHA) grade II or greater congestive heart failure, or serious cardiac arrhythmia requiring medication

• Uncontrolled hypertension

• Prolonged QTc interval (congenital or acquired)

• Patient with significant peripheral vascular disease

• Clinical signs of CNS involvement

• Patients with active or uncontrolled systemic disease/infections or with serious illness or medical conditions, which is incompatible with the protocol

• Symptomatic peripheral neuropathy = grade 1 according the NCI CTCAE v.3.0.

• Known hypersensitivity/allergic reaction or contraindications to human albumin preparations or to any of the excipients

• Known hypersensitivity/allergic reaction or contraindications to platinum compounds or fluoropyrimidines

• Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol

• Pregnancy or lactation.

• Patients - both males and females - with reproductive potential (i.e. menopausal for less than 1-year and not surgically sterilized) must practice effective contraceptive measures throughout the study.

• Women of childbearing potential must provide a negative pregnancy test (serum or urine) within 14 days prior to registration

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Colon Cancer
• Colorectal Neoplasms

Intervention

Drug:
• NGR-hTNF
iv 0.8 or 45 mcg/sqm q3W
• Oxaliplatin
iv q3W 100 mg/sqm 60 minutes after NGR-hTNF infusion
• capecitabine
orally 825 mg/sqm 2qDx14

Locations

Country	Name	City	State
Italy	Azienda Ospedaliera Universitaria San Martino	Genoa

Sponsors (1)

Lead Sponsor	Collaborator
MolMed S.p.A.

Country where clinical trial is conducted

Italy, 

References & Publications (1)

Mammoliti S, Andretta V, Bennicelli E, Caprioni F, Comandini D, Fornarini G, Guglielmi A, Pessino A, Sciallero S, Sobrero AF, Mazzola G, Lambiase A, Bordignon C. Two doses of NGR-hTNF in combination with capecitabine plus oxaliplatin in colorectal cancer — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To determine the feasibility and safety of NGRhTNF administered at low (0.8 mcg/sqm) and high (45 mcg/sqm) doses in combination with a standard oxaliplatin-based regimen in two sequential cohorts of patients with metastatic colorectal cancer.		during the study	Yes
Secondary	Document the preliminary antitumor activity in terms of objective response rate (according to RECIST criteria) and progression-free survival		during the study	No
Secondary	Evaluate the pharmacokinetic profile of NGRhTNF and to measure plasma levels of sTNF-RI and sTNF-RII		before during and following the treatment	No